Jun 2026 (Q1 FY27) — Jul 29, 2026
Houlihan Lokey Q1 FY27 — Corporate Finance Headwinds Offset by FVA Growth
Read the full callHoulihan Lokey (HLI) earnings
- Jun 2026
- Jun 2026 (Q1 FY27)
- Mar 2026
Houlihan Lokey earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 511 | −15.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 15.3 | +0.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 78.0 | −20.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$127.07 −1.91% · −$2.48
Performance −33.2% 1Y
1Y: $190.19 on 17 Oct 2025 → $127.07. High $202.25 (27 Oct 2025), low $123.39 (10 Aug 2026).
- Previous close
- $129.55
- 52-week range
- $123.39 – $202.25
- One year
- −34.04%
Overview
- Symbol
- HLI
- Sector
- Financials
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q4 FY26) — May 6, 2026
Houlihan Lokey Q4 FY26 — Record Annual Revenue and EPS, Strong Backlog
Read the full callEvery analysed call
Houlihan Lokey earnings calls (HLI)
Financials
What the filings say
Net profit, year on year: −20% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 575 | 634 | 666 | 605 | 659 | 717 | 636 | 511 |
| Operating profit | 131 | 136 | 139 | 90 | 151 | 161 | 125 | 78 |
| Operating margin | 22.7% | 21.4% | 20.9% | 14.9% | 22.9% | 22.4% | 19.7% | 15.3% |
| Other income | 5 | 9 | 11 | 8 | 9 | 9 | 9 | 8 |
| Profit before tax | 136 | 145 | 150 | 98 | 160 | 170 | 135 | 86 |
| Tax rate | 31.3% | 34.3% | 18.9% | 0.0% | 30.2% | 31.3% | 26.9% | 9.3% |
| Net profit | 94 | 95 | 122 | 98 | 112 | 117 | 100 | 78 |
| EPS ($ per share) | 1.42 | 1.45 | — | 1.47 | 1.67 | 1.75 | — | 1.17 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Reserves | 276 | 377 | 600 | 922 | 1,033 | 1,163 | 1,395 | 1,645 |
| Total liabilities | 535 | 693 | 1,043 | 1,443 | 1,356 | 1,334 | 1,645 | 1,856 |
| Fixed assets | 31 | 42 | 46 | 52 | 88 | 137 | 149 | 143 |
| Total assets | 1,426 | 1,677 | 2,426 | 2,887 | 2,969 | 3,171 | 3,820 | 4,309 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 224 | 288 | 580 | 737 | 136 | 328 | 849 | 704 |
| Cash from investing | 6 | -33 | -100 | -274 | -3 | -70 | -265 | 2 |
| Cash from financing | -236 | -152 | -27 | -459 | -240 | -251 | -329 | -493 |
| Net cash flow | -14 | 95 | 466 | -13 | -119 | 7 | 254 | 218 |
| Capital expenditure | -7 | -21 | -14 | -9 | -51 | -67 | -40 | -22 |
| Free cash flow | 218 | 267 | 566 | 728 | 86 | 262 | 809 | 682 |
HLI revenue by segment
Corporate Finance shrank from 63% to 59% of revenue over the last two years.
| Segment | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Corporate Finance | 63% | 66% | 62% | 66% | 67% | 66% | 68% | 59% | -24.0% |
| Financial Restructuring | 23% | 21% | 25% | 21% | 20% | 22% | 17% | 23% | -7.2% |
| Financial Advisory Services | 14% | 13% | 13% | 13% | 13% | 12% | — | 17% | +13.2% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
HLI operating KPIs by quarter
| KPI | Mar 2026 Q4 FY26 | Jun 2026 Q1 FY27 | Change vs prior quarter |
|---|---|---|---|
| Closed transactions Corporate Finance | 171We closed 171 transactions this quarter, up from 147 in the same period last year and our average transaction fee on closed deals decreased.Source: earnings call transcript | 127We closed 127 transactions this quarter basically flat with the same period last year.Source: earnings call transcript | -25.7% |
| Closed transactions Financial Restructuring | 30We closed 30 transactions this quarter, down 21% from the same quarter last year and our average transaction fee on closed deals decreased.Source: earnings call transcript | 23We closed 23 transactions this quarter, down 34% from the same period last year, but our average transaction fee on closed deals increased.Source: earnings call transcript | -23.3% |
| Fee events Financial and Valuation Advisory | 1,248We had 1,248 fee events during the quarter compared to 1,224 in the same period last year, a 2% increase.Source: earnings call transcript | 1,042We had 1,042 fee events during the quarter compared to 957 in the same period last year, a 9% increase.Source: earnings call transcript | -16.5% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q1 FY2027 · share of revenue
- US 71% ↓ 4 pt
- Non Us 29% ↑ 4 pt
As HLI cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
23 filings between Nov 10, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
$500.6K
1 purchase by 1 insider
Sales
$2.09M
5 sales by 3 insiders
40% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 7
- Award — granted as compensation
Also filed: 7 conversions, 3 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| BEISER SCOTT L | — | $941.4K | May 21, 2026 |
| SCHRIESHEIM ROBERT A | — | $854.3K | Feb 6, 2026 |
| ALLEY J LINDSEY | $500.6K | — | Aug 3, 2026 |
| CRAIN CHRISTOPHER M | — | $298.9K | Sep 10, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Reichert Thomas Director | Award | 925 | $0 |
| Sep 10, 2026 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Conversion | 1,000 | $0 |
| Sep 10, 2026 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Sale | 1,000 | $140.2K |
| Aug 3, 2026 | ALLEY J LINDSEY Chief Financial Officer | Purchase | 4,020 | $500.6K |
| May 21, 2026 | Zucker Gillian Beth Director | Award | 996 | $0 |
| May 21, 2026 | Bassey Ekpedeme M Director | Award | 797 | $0 |
| May 21, 2026 | Walker Cyrus D. Director | Award | 996 | $0 |
| May 21, 2026 | BEISER SCOTT L CO-CHAIRMAN | Conversion | 6,265 | $0 |
| May 21, 2026 | BEISER SCOTT L CO-CHAIRMAN | Sale | 6,265 | $941.4K |
| May 21, 2026 | ZUBER PAUL ANDREW Director | Award | 797 | $0 |
| May 21, 2026 | Mund Ronald Scott Director | Award | 476 | $0 |
| May 21, 2026 | SCHRIESHEIM ROBERT A Director | Award | 1,129 | $0 |
| Apr 1, 2026 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Sale 10b5-1 plan | 500 | $71.7K |
| Apr 1, 2026 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Conversion 10b5-1 plan | 500 | $0 |
| Feb 6, 2026 | SCHRIESHEIM ROBERT A Director | Sale | 5,000 | $854.3K |
| Jan 2, 2026 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Conversion 10b5-1 plan | 500 | $0 |
| Jan 2, 2026 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Sale 10b5-1 plan | 500 | $87.1K |
| Dec 5, 2025 | GOLD IRWIN CO-CHAIRMAN | Gift | 5,000 | $0 |
| Dec 5, 2025 | GOLD IRWIN CO-CHAIRMAN | Conversion | 5,000 | $0 |
| Nov 26, 2025 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Gift | 1,200 | $0 |
| Nov 26, 2025 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Conversion | 1,200 | $0 |
| Nov 10, 2025 | BEISER SCOTT L CO-CHAIRMAN | Conversion | 8,000 | $0 |
| Nov 10, 2025 | BEISER SCOTT L CO-CHAIRMAN | Gift | 8,000 | $0 |
| Oct 1, 2025 | Mund Ronald Scott Director | Award | 483 | $0 |
| Sep 16, 2025 | GOLD IRWIN CO-CHAIRMAN | Conversion | 6,811 | $0 |
| Sep 16, 2025 | GOLD IRWIN CO-CHAIRMAN | Sale | 6,811 | $1.38M |
| Sep 2, 2025 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Sale 10b5-1 plan | 500 | $98.1K |
| Sep 2, 2025 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Conversion 10b5-1 plan | 500 | $0 |
| Aug 27, 2025 | SIEGERT PAUL ERIC CO-CHAIRMAN | Sale | 40,000 | $8.00M |
| Aug 27, 2025 | SIEGERT PAUL ERIC CO-CHAIRMAN | Conversion | 40,000 | $0 |
| Jul 14, 2025 | Zucker Gillian Beth Director | Sale 10b5-1 plan | 200 | $38.3K |
| Jun 30, 2025 | GOLD IRWIN CO-CHAIRMAN | Conversion | 5,000 | $0 |
| Jun 30, 2025 | GOLD IRWIN CO-CHAIRMAN | Sale | 5,000 | $914.0K |
| Jun 26, 2025 | GOLD IRWIN CO-CHAIRMAN | Gift | 5,000 | $0 |
| Jun 24, 2025 | GOLD IRWIN CO-CHAIRMAN | Conversion | 5,000 | $0 |
| Jun 13, 2025 | Zucker Gillian Beth Director | Sale 10b5-1 plan | 200 | $34.9K |
| Jun 2, 2025 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Sale 10b5-1 plan | 500 | $86.5K |
| Jun 2, 2025 | CRAIN CHRISTOPHER M GENERAL COUNSEL | Conversion 10b5-1 plan | 500 | $0 |
| May 22, 2025 | Zucker Gillian Beth Director | Award | 732 | $0 |
| May 22, 2025 | Bassey Ekpedeme M Director | Award | 563 | $0 |
| May 22, 2025 | Walker Cyrus D. Director | Award | 732 | $0 |
| May 22, 2025 | ZUBER PAUL ANDREW Director | Award | 563 | $0 |
| May 22, 2025 | KOSECOFF JACQUELINE B Director | Award | 563 | $0 |
| May 22, 2025 | SCHRIESHEIM ROBERT A Director | Award | 845 | $0 |
| May 19, 2025 | BEISER SCOTT L CO-CHAIRMAN | Gift | 15,000 | $0 |
| May 19, 2025 | BEISER SCOTT L CO-CHAIRMAN | Conversion | 8,008 | $0 |
| May 19, 2025 | BEISER SCOTT L CO-CHAIRMAN | Sale | 8,008 | $1.43M |
| May 19, 2025 | BEISER SCOTT L CO-CHAIRMAN | Conversion | 15,000 | $0 |
| May 13, 2025 | Zucker Gillian Beth Director | Sale 10b5-1 plan | 200 | $35.7K |
| Apr 14, 2025 | Zucker Gillian Beth Director | Sale 10b5-1 plan | 200 | $30.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for HOULIHAN LOKEY, INC.
Free account. Everything above stays public.
Write why you follow HOULIHAN LOKEY, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading